Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308496 | 0.85 | KMT2A (0.43) | MAPK14ALDH1A1KMT2APARP1ROCK2 | |
| SCHEMBL6302201 | 0.84 | MAPK1 (0.47) | MAPK14MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL5592041 | 0.74 | MEN1 (0.62) | MAPK7MAPK14TDP1KDM4EUSP2 | |
| SCHEMBL949150 | 0.73 | CCNC (0.41) | MAPK14KDM4ECCNCCDK8 | |
| SCHEMBL5255788 | 0.72 | MAPK14 (0.53) | MAPK14MAPK1ROCK2GRK2 | |
| SCHEMBL1849928 | 0.72 | SMN1; SMN2 (0.58) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7462082 | 0.71 | IKBKB (0.50) | MEN1KMT2APARP1 | |
| SCHEMBL6302054 | 0.70 | MAPK1 (0.40) | MAPK14MAPK1MAPK3ROCK2GRK2 | |
| SCHEMBL1846600 | 0.69 | MEN1 (0.60) | MAPK14KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6302465 | 0.68 | GSK3B (0.41) | MAPK14KDM4EMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | claimed |
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | claimed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | claimed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| US-6852740-B2 | Pyrazole derivatives as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6503930-B1 | Treating cytokine-mediated diseases, such as inflammation | G.D. SEARLE & COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | MAPK1, MAPK3, MAP3K1 | MAPK7 29/4885MAPK14 26/4885TDP1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.